The impact of IL-6 on muscle degradation was investigated in a study in which tocilizumab, an anti-IL-6 receptor antibody, was used for 1 year in patients with RA; these patients saw an increase in muscle mass as compared to the muscle mass that they had at the beginning of the study [83]. The gene discussed is IL6; the disease is rheumatoid arthritis.